

## Special Issue

# Role of Immune Checkpoint Inhibitors or Targeted Therapy in the Treatment of Patients with Melanoma Volume II

### Message from the Guest Editors

The past few years have brought revolutionary new treatments to melanoma patients, including checkpoint inhibitors and targeted therapy for both patients receiving adjuvant treatment as well as treatment for metastatic disease. Melanoma has become a model disease for developing new immunotherapies, and new drugs are constantly under development. We are very much in need of more knowledge about biomarkers to select the right patient for the right treatment, to become more effective at treating the immune-mediated adverse events in these patients, and to overcome immune resistance. We need to examine the effect of these new treatment strategies in all subgroups of melanoma patients, including ocular and mucosal melanoma, and we need to explore treatment combinations, as well as real-life benefits.

### Guest Editors

Dr. Henrik Schmidt

Department of Oncology, Aarhus University Hospital, DK-8200 Aarhus, Denmark

Dr. Eva Ellebæk

Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, DK-2730 Herlev, Denmark

### Deadline for manuscript submissions

closed (20 September 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/164080](https://mdpi.com/si/164080)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)